- First quarter financial results to be released on May 13, 2009 -

    Toronto Stock Exchange Symbol: DND

    MISSISSAUGA, ON, May 7 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: DND),
will host a conference call on Wednesday, May 13, 2009 at 8:30 a.m. (ET) to
discuss its fiscal 2009 first quarter financial results. Cipher invites all
interested parties to participate. You can join the call by dialing
416-644-3424 or 1-800-731-5319. Please call in 15 minutes prior to the call to
secure a line. You will be put on hold until the conference call begins.
    Larry Andrews, President and CEO, will chair the call. A question and
answer session will follow, at which time the operator will direct
participants as to the correct procedure for submitting questions. A taped
replay of the conference call will be available until Wednesday, May 20, 2009
by calling 416-640-1917 or 1-877-289-8525, reference number 21303963 followed
by the number sign.
    A live audio webcast of the conference call will be available through
www.cipherpharma.com. Please connect at least 15 minutes prior to the
conference call to ensure adequate time for any software download that may be
needed to hear the webcast. An archived replay of the webcast will be
available for 365 days.

    About Cipher Pharmaceuticals Inc.

    Cipher Pharmaceuticals is a drug development company focused on
commercializing novel formulations of successful, currently marketed molecules
using advanced drug delivery technologies. Cipher's strategy is to in-license
products that incorporate proven drug delivery technologies and advance them
through the clinical development and regulatory approval stages, after which
the products are out-licensed to international partners. Because Cipher's
products are based on proven technology platforms applied to currently
marketed drugs, they are expected to have lower approval risk, shorter
development timelines and significantly lower development costs. The Company's
lead compound, CIP-FENOFIBRATE, received final approval from the U.S. Food and
Drug Administration and Health Canada in the first quarter of 2006. The
product is being marketed in the United States by Kowa Pharmaceuticals America
under the label Lipofen(R). In addition, Cipher is developing formulations of
the pain reliever tramadol (tentative FDA approval in February 2009) and the
acne treatment isotretinoin (FDA approvable letter in April 2007).
    Cipher is listed on the Toronto Stock Exchange under the symbol 'DND' and
has approximately 24 million shares outstanding. For more information, please
visit www.cipherpharma.com.